10:06 AM EST - Resverlogix Corp. : Announced that on Friday, May 25, at the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress in Copenhagen, Denmark, the Company is supporting a symposium titled: "Epigenetics in CKD & CVD: A potential breakthrough therapy?” The symposium highlights the role of epigenetics and BET-inhibition in chronic kidney disease and cardiovascular disease, especially in patients with diabetes mellitus, and the significant unmet need that still exists in this patient population. Resverlogix Corp.
shares T.RVX are trading up $0.06 at $1.54.